NEW YORK (GenomeWeb News) – Sequenom and CombiMatrix today announced an agreement to market chromosomal microarray analysis testing services "to broaden and confirm the results of non-invasive prenatal testing" to doctors and patients.

Under the terms of the deal, the Sequenom Center for Molecular Medicine and CombiMatrix will promote the use of NIPD testing and CMA, as well as provide technical training to physicians. They also will provide counseling, educational, and support services to physicians and their patients, they said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Apr
03
Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.